Concurrent Refractory Atopic Dermatitis and Generalized Vitiligo Successfully Treated with Abrocitinib: A Case Report

Atopic dermatitis (AD) may sometimes be comorbid with vitiligo. However, these therapeutic agents are often slow acting and lead to various adverse effects, resulting in poor patient compliance. This report describes a 65-year-old male patient with refractory moderate-to-severe atopic dermatitis (AD) and generalized vitiligo. The patient was treated with repeated antihistamine and dupilumab injections; however, erythema and pruritus did not improve. Consequently, oral abrocitinib was administered to treat AD and vitiligo, and the patient's generalized erythema, papules, and pruritus ameliorated with the repigmentation of vitiligo lesions. This case provided evidence of the efficacy and safety of oral abrocitinib for patients with concurrent refractory AD and vitiligo.

Authors

Institutions

Publication Details

Journal
Journal of Asthma and Allergy
Published
2024-12-01
DOI
https://doi.org/10.2147/jaa.s492614
Citations
4
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
2.14

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Concurrent Refractory Atopic Dermatitis and Generalized Vitiligo Successfully Treated with Abrocitinib: A Case Report

Shuang Chen, Xingyu Pan, Jin Chen, Yan Zhu et al.
4 citations
Journal of Asthma and Allergy
Dermatology and Skin Diseases
2.14
article

Concurrent Refractory Atopic Dermatitis and Generalized Vitiligo Successfully Treated with Abrocitinib: A Case Report

Shuang Chen, Xingyu Pan, Jin Chen, Yan Zhu, Yangmei Chen, Xinyi Shao
article en
4 citations

Abstract

Atopic dermatitis (AD) may sometimes be comorbid with vitiligo. However, these therapeutic agents are often slow acting and lead to various adverse effects, resulting in poor patient compliance. This report describes a 65-year-old male patient with refractory moderate-to-severe atopic dermatitis (AD) and generalized vitiligo. The patient was treated with repeated antihistamine and dupilumab injections; however, erythema and pruritus did not improve. Consequently, oral abrocitinib was administered to treat AD and vitiligo, and the patient's generalized erythema, papules, and pruritus ameliorated with the repigmentation of vitiligo lesions. This case provided evidence of the efficacy and safety of oral abrocitinib for patients with concurrent refractory AD and vitiligo.

Journal of Asthma and AllergyVol. Volume 17
The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Chongqing Medical University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Chongqing
Zero hunger
Openalex Percentile: Top 12%
Dermatology and Skin Diseases
2.14
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.